Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AstraZeneca Pharma IndiaNSE:ASTRAZEN -1.77%90 3-Year EBITDA Growth Rate is 23.60% as of Jun. 2026, which is 23% above its 10-year median of 19.25. GuruFocus rates NSE:ASTRAZEN with a GF Score™ of 90/100 and a GF Value™ of ₹11,334.45 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 809 Drug Manufacturers companies, AstraZeneca Pharma India ranks better than 73.42% on this metric.
During the past 12 months, AstraZeneca Pharma India's average EBITDA Per Share Growth Rate was -16.50% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 23.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 17.90% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 26.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of AstraZeneca Pharma India was 73.60% per year. The lowest was -37.40% per year. And the median was 19.25% per year.
AstraZeneca Pharma India (NSE:ASTRAZEN) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
AstraZeneca Pharma India 3-Year EBITDA Growth Rate Related Terms
NSE:ASTRAZEN vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AstraZeneca Pharma India's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AstraZeneca Pharma India 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AstraZeneca Pharma India's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where AstraZeneca Pharma India's 3-Year EBITDA Growth Rate falls into.
AstraZeneca Pharma India 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 23.60% mean?
AstraZeneca Pharma India (NSE:ASTRAZEN) has a 3-Year EBITDA Growth Rate of 23.60% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for AstraZeneca Pharma India and its competitors. This is 23% above median its historical median of 19.25. According to the industry distribution chart, AstraZeneca Pharma India ranks #215 out of 809 companies in the Drug Manufacturers industry, placing it in the top 26.6%.
Is AstraZeneca Pharma India's 3-Year EBITDA Growth Rate too high?
AstraZeneca Pharma India's current 3-Year EBITDA Growth Rate of 23.60% is 23% above median its 10-year median of 19.25. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. AstraZeneca Pharma India's value of 23.60% is 168.2% above this industry median. Based on the distribution chart, AstraZeneca Pharma India ranks #215 out of 809 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, AstraZeneca Pharma India has a GF Score™ of 90/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca Pharma India's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, AstraZeneca Pharma India ranks #215 out of 809 companies for 3-Year EBITDA Growth Rate. This puts AstraZeneca Pharma India in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.80. AstraZeneca Pharma India's value of 23.60% is 168.2% above this benchmark. While the company's 10-year median is 19.25 vs. the industry median of 8.80, AstraZeneca Pharma India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AstraZeneca Pharma India's current 3-Year EBITDA Growth Rate of 23.60% is 168.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for AstraZeneca Pharma India and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AstraZeneca Pharma India's current 3-Year EBITDA Growth Rate is 23.60%, which is 23% above median its own 10-year median of 19.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca Pharma India stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca Pharma India (NSE:ASTRAZEN) is currently considered Possible Value Trap. The stock's GF Value™ is ₹11,334.45, compared to a current price of ₹7,946.50 — trading 29.9% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 23.60%, which is 23% above median its 10-year median of 19.25 and 168.2% above the Drug Manufacturers industry median of 8.80. AstraZeneca Pharma India's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For AstraZeneca Pharma India (NSE:ASTRAZEN), the current 3-Year EBITDA Growth Rate is 23.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AstraZeneca Pharma India (NSE:ASTRAZEN) Overvalued in 2026?
Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued.
The current stock price of ₹7,946.50 is trading 29.9% below its estimated GF Value™ of ₹11,334.45.
GuruFocus considers AstraZeneca Pharma India to be Possible Value Trap.
Key valuation signals for NSE:ASTRAZEN:
3-Year EBITDA Growth Rate: 23.60% (23% above median its 10-year median of 19.25)
GF Value™: ₹11,334.45 vs. price of ₹7,946.50 (29.9% below fair value)
Industry Position: 168.2% above the Drug Manufacturers median (#215 of 809)
No single metric tells the full story. See the NSE:ASTRAZEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
90GF Score
Get the complete analysis for NSE:ASTRAZEN
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ASTRAZEN has been successfully added to your 
